ExploreWatchlistsPricing
  1. JP-listed companies
  2. SymBio Pharmaceuticals Limited
  3. Financials
  4. Pretax margin (%)

SymBio Pharmaceuticals Limited (4582)

Market cap
¥6.6B
P/E ratio
-1.3x
Symbiopharm develops drugs for rare diseases in cancer and viral infections, focusing on compounds with proven human efficacy to reduce development risks.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndPretax margin (%) YoY (%)
Dec 31, 2025-355.4+136.31%
Dec 31, 2024-150.4+1042.12%
Dec 31, 2023-13.2-165.91%
Dec 31, 202220+64.80%
Dec 31, 202112.1-107.85%
Dec 31, 2020-154.5+0.20%
Dec 31, 2019-154.2+115.21%
Dec 31, 2018-71.7-37.93%
Dec 31, 2017-115.5+18.02%
Dec 31, 2016-97.8-28.10%
Dec 31, 2015-136.1+139.57%
Dec 31, 2014-56.8-45.67%
Dec 31, 2013-104.5+18.17%
Dec 31, 2012-88.5-20.53%
Dec 31, 2011-111.3

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat